Haugen Janet Brutschea reported grant involving 44 derivative units of WEST PHARMACEUTICAL SERVICES INC at $370.76 for $16.3k on Sep 30, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Oct 2, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$16,313.44Shares × reported price
Shares traded
44Phantom Stock Unit
Price per share
$370.76Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
350.87Direct
Trade date
Sep 30, 2026Grant
Filed
Oct 2, 2026, 1:10 PM ET2-day reporting delay
Accession
0000105770-26-000112Code A · Transaction 233945
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

WST price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
WST · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −6.5%1w ago +3%1d ago +3.2%
Returns since7d +0.3%30d +13%90d180d1y

Footnotes in full

F1: Reflects 791 shares of restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director.